SaeGwang Park, MD PhD is a CEO/Co-founder of Nexthera Co. Ltd. And a professor at Inje University College of Medicine INJE University in the Department of Microbiology and Immunology. I had expertise in the engineering of recombinant protein and the efficacy and mechanism study in animal models. Based on academic research, I am developing three key technologies of NexThera; NT-101 is a novel eye-drop therapeutic for wet-AMD; NT-2 platform is an innovative protein polymer platform technology that leverages self-assembly properties for the development of bio-betters; NT-3 is the protein translation inhibitors for hematologic cancer.
Speaking In
1:15 PM - 1:30 PM
Monday, June 5
